The official website of the Medicine Evaluation Center of the National Medical Products Administration revealed that that the clinical trial application of the new medicine LK101 injection had been approved for the treatment of late-stage solid tumors. The vaccine was developed by Likang Life Sciences. 

A screenshot of the approval of the National Medical Products Administration for LK101 injection developed by Likang Life Sciences [Photo/beijingetown.com.cn]

This is the first personalized neoantigen vaccine approved for clinical trials in China, and also the first personalized (messenger ribonucleic acid) mRNA tumor vaccine approved for clinical trials in China. This is a milestone event in the field of mRNA tumor vaccines in China.

Since its establishment to entering clinical trials, Likang Life Sciences has independently established four major technology and product platforms. With the promotion of these basic platforms, innovative research and development has gradually entered a stage of rapid progress.

"The innovation of enterprises cannot be separated from the 'nursery' of Beijing E-Town, which helps us to find office and R&D sites," said Chen Li, founder of Likang Life Sciences.

Since the construction of the "Two Zones", Beijing E-Town has continuously innovated its work methods and solved problems such as bottleneck, difficulty, and pain points of the biopharmaceutical innovation chain and industrial chain, creating an open "Beijing E-Town model" for the entire biopharmaceutical industry. 

"Several policies in the '1+2' support policy for the construction of a global 'new medicine intelligent manufacturing' industry highland recently issued by Beijing E-Town match the development of our company, such as cooperation between industry, academia, and research, and project landing. After being implemented, they can provide certain financial support for our subsequent innovative research and development," Chen added.

The registration and evaluation of 23-valent pneumococcal polysaccharide vaccine developed by Beijing Zhifei Lvzhu Biopharmaceutical is underway and is expected to be launched this year. SinoCellTech expects to have two new medicines approved for marketing this year. Multiple products of vaccine companies are in different clinical stages. 

Since the beginning of this year, vaccine companies in Beijing E-Town have been working at full capacity. With Beijing E-Town's announcement to build a global "new medicine intelligent manufacturing" industry highland, it will further fill in the industry support chain, improve the industrial ecological environment.